MTVA Stock Summary and Trading Ideas (Metavia | NASDAQ:MTVA)

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Metavia trades on the NASDAQ stock market under the symbol MTVA.

As of December 5, 2025, MTVA stock price climbed to $8.18 with 119,386 million shares trading.

MTVA has a beta of 1.15, meaning it tends to be more sensitive to market movements. MTVA has a correlation of 0.04 to the broad based SPY ETF.

MTVA has a market cap of $207.82 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that MTVA belongs to (by Net Assets): VXF, VTI.

MTVA has underperformed the market in the last year with a return of -67.7%, while SPY returned +14.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MTVA shares. However, MTVA has outperformed the market in the last 3 month and 2 week periods, returning +7.8% and +7.1%, while SPY returned +6.2% and +4.0%, respectively. This indicates MTVA has been having a stronger performance recently.

MTVA support price is $6.57 and resistance is $8.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTVA shares will trade within this expected range on the day.